MGNX - MacroGenics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Rockville,
United States
Type: Equity
MGNX price evolution
MGNX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $83.93 | $80.36 | $100.96 | |
| Short term investments | $56.44 | $103.88 | $128.85 | |
| Net receivables | $8.75 | $6.19 | $7.22 | $10.37 |
| Inventory | $3.24 | $1.11 | $1.25 | $1.22 |
| Total current assets | $222.2 | $156.95 | $202.57 | $251.34 |
| Long term investments | ||||
| Property, plant & equipment | $41.11 | $43 | $44.52 | $45.69 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $44.19 | $45.71 | $47.08 | |
| Total investments | $56.44 | $103.88 | $128.85 | |
| Total assets | $264.49 | $201.14 | $248.28 | $298.42 |
| Current liabilities | ||||
| Accounts payable | $6.61 | $5.24 | $10.69 | $6.44 |
| Deferred revenue | $79.32 | $79.02 | $80.89 | |
| Short long term debt | $4.41 | $4.08 | $3.77 | |
| Total current liabilities | $59.31 | $57.91 | $55.76 | $56.11 |
| Long term debt | $29.65 | $29.93 | $30.2 | |
| Total noncurrent liabilities | $85.41 | $86.37 | $89.7 | |
| Total debt | $34.06 | $34.01 | $33.97 | |
| Total liabilities | $144.43 | $143.32 | $142.13 | $145.81 |
| Shareholders' equity | ||||
| Retained earnings | -$1154.3 | -$1210.61 | -$1154.94 | -$1102.75 |
| Other shareholder equity | $0.01 | -$0.02 | -$0.04 | -$0.01 |
| Total shareholder equity | $57.82 | $106.15 | $152.61 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $100.96 | $108.88 | $123.47 | $181.13 |
| Short term investments | $128.85 | $45.46 | $120.15 | $91.4 |
| Net receivables | $10.37 | $56.22 | $10.39 | $23.08 |
| Inventory | $1.22 | $1.45 | $4.39 | |
| Total current assets | $251.34 | $222.18 | $279.56 | $312.59 |
| Long term investments | ||||
| Property, plant & equipment | $45.69 | $56.91 | $37.68 | $42.23 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $47.08 | $58.29 | $55.69 | $66.15 |
| Total investments | $128.85 | $45.46 | $120.15 | $91.4 |
| Total assets | $298.42 | $280.47 | $335.25 | $378.74 |
| Current liabilities | ||||
| Accounts payable | $6.44 | $4.9 | $15.5 | $8.03 |
| Deferred revenue | $80.89 | $69.47 | $20.65 | $11.38 |
| Short long term debt | $3.77 | $4.73 | $4.68 | $3.99 |
| Total current liabilities | $56.11 | $48.61 | $74.58 | $50.67 |
| Long term debt | $30.2 | $30.11 | $20.79 | $25.26 |
| Total noncurrent liabilities | $89.7 | $89.84 | $21.05 | $32.19 |
| Total debt | $33.97 | $34.83 | $25.47 | $29.25 |
| Total liabilities | $145.81 | $138.46 | $95.63 | $82.86 |
| Shareholders' equity | ||||
| Retained earnings | -$1102.75 | -$1093.69 | -$973.94 | -$771.82 |
| Other shareholder equity | -$0.01 | -$0.01 | -$0.06 | -$0.01 |
| Total shareholder equity | $152.61 | $142.01 | $239.62 | $295.88 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $110.71 | $10.8 | $9.1 | $10.72 |
| Cost of revenue | $2.82 | $2.12 | $0.16 | |
| Gross Profit | $108.84 | $7.97 | $6.99 | $10.56 |
| Operating activities | ||||
| Research & development | $51.73 | $46.03 | $47.35 | |
| Selling, general & administrative | $14.42 | $14.71 | $12.56 | |
| Total operating expenses | $54.65 | $66.16 | $60.74 | $59.91 |
| Operating income | -$58.18 | -$53.75 | -$49.35 | |
| Income from continuing operations | ||||
| EBIT | -$55.66 | -$51.06 | -$46.07 | |
| Income tax expense | ||||
| Interest expense | $0.01 | $1.13 | ||
| Net income | ||||
| Net income | $56.31 | -$55.66 | -$52.19 | -$46.07 |
| Income (for common shares) | -$55.66 | -$52.19 | -$46.07 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $58.75 | $151.94 | $77.45 | $104.88 |
| Cost of revenue | $8.22 | $7.38 | $2.65 | |
| Gross Profit | $50.53 | $144.56 | $74.8 | $104.88 |
| Operating activities | ||||
| Research & development | $166.58 | $207.03 | $214.58 | $193.2 |
| Selling, general & administrative | $52.19 | $58.95 | $63.01 | $42.74 |
| Total operating expenses | $218.77 | $265.98 | $277.59 | $235.94 |
| Operating income | -$168.24 | -$121.42 | -$202.79 | -$131.06 |
| Income from continuing operations | ||||
| EBIT | -$7.63 | -$119.76 | -$202.12 | -$129.74 |
| Income tax expense | ||||
| Interest expense | $1.43 | |||
| Net income | ||||
| Net income | -$9.06 | -$119.76 | -$202.12 | -$129.74 |
| Income (for common shares) | -$9.06 | -$119.76 | -$202.12 | -$129.74 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$55.66 | -$52.19 | -$46.07 | |
| Operating activities | ||||
| Depreciation | $2.42 | $2.46 | $2.69 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.65 | $5.55 | $4.36 | |
| Total cash flows from operations | -$44.48 | -$45.64 | -$28.04 | |
| Investing activities | ||||
| Capital expenditures | -$0.95 | -$1.46 | -$0.62 | |
| Investments | $48.39 | $26.25 | $39.44 | |
| Total cash flows from investing | $107.83 | $47.44 | $24.79 | $38.82 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.63 | $2.64 | $0.27 | |
| Net borrowings | -$0 | |||
| Total cash flows from financing | $0.81 | $0.63 | $0.25 | $0.27 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $78.67 | $3.58 | -$20.6 | $11.06 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$9.06 | -$119.76 | -$202.12 | -$129.74 |
| Operating activities | ||||
| Depreciation | $13.13 | $11.87 | $11.26 | $11.96 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $18.37 | $20.44 | $23.13 | $20.68 |
| Total cash flows from operations | -$78.2 | -$86.96 | -$143.83 | -$111.9 |
| Investing activities | ||||
| Capital expenditures | -$1.7 | -$3.62 | -$6.2 | -$5.91 |
| Investments | -$78.38 | $74.34 | -$30.41 | -$1.88 |
| Total cash flows from investing | -$80.08 | $70.72 | -$36.61 | -$7.79 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.17 | $1.66 | $122.78 | $174.34 |
| Net borrowings | $149.5 | |||
| Total cash flows from financing | $150.36 | $1.66 | $122.78 | $174.34 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$7.93 | -$14.59 | -$57.66 | $54.66 |
News
Fundamentals
| Market cap | $104.19M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 62.76M |
| Revenue | $141.33M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$97.62M |
| Revenue Q/Q | 964.81% |
| Revenue Y/Y | 16.68% |
| P/E ratio | -1.07 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.74 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.56 |
|---|---|
| ROA | -38.57% |
| ROE | N/A |
| Debt/Equity | 0.96 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.75 |
| Quick ratio | 3.69 |